Abiopharma

News list

ALLARITY THERAPEUTICS, INC. (ALLR)

SEC News
May 06, 2026, 12:05 UTC

(85% Positive) ALLARITY THERAPEUTICS, INC. (ALLR) Announces Enrollment Update for confidence Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment

Full text

News bot May 6, 2026, 12:06 p.m.

📋 ALLARITY THERAPEUTICS, INC. (ALLR) - Clinical Trial Update

Filing Date: 2026-05-06

Accepted: 2026-05-06 08:05:42

Event Type: Clinical Trial Update

Event Details:

ALLARITY THERAPEUTICS, INC. (ALLR) Announces Clinical Trial Update ALLARITY THERAPEUTICS, INC. (ALLR) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: confidence, outlays
Diseases/Conditions: potential pivotal-stage clinical development, advanced
Clinical Stage: pivotal trial, Phase 3
Collaboration: FDA

🔬 Clinical Development Pipeline (ALLARITY THERAPEUTICS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Drug Response Predictor® (DRP)	Drug	Preclinical	Ovarian Cancer	ClinicalTrials.gov
PARP inhibitor 2X-121	Other	Phase PHASE2	Metastatic Breast Cancer	ClinicalTrials.gov
APO010	Other	Phase PHASE1	Relapsed/Refractory Multiple Myeloma	ClinicalTrials.gov
LiPlaCis	Other	Phase PHASE1	Phase 1: Advanced or Refractory Solid Tumours	ClinicalTrials.gov
2X-121 and dovitinib	Other	Phase PHASE1	Advanced Solid Tumors	ClinicalTrials.gov
2X-121	Other	Phase PHASE2	Advanced Ovarian Cancer	ClinicalTrials.gov
Ixabepilone Injection	Other	Phase PHASE2	Metastatic Breast Cancer	ClinicalTrials.gov
Irofulven	DRUG	Phase PHASE2	Metastatic Castration-Resistant Prostate Cancer Patients	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: ALLARITY THERAPEUTICS, INC.
Ticker Symbol: ALLR